Do JAK-STAT Inhibitors confer increased risk of vascular complications in dermatology patients?
Australia: Evolving evidence suggests that dermatology patients receiving Janus kinase–signal transducer and activator of transcription inhibitors (JAK-STATi) may be at increased risk of venous thromboembolism (VTE) and major adverse cardiovascular events (MACE). Most existing literature focused on indications that may confer a higher risk of MACE and VTE than that among patients with isolated dermatological […]